All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Pandit, 2021 0.95 [0.02; 50.33]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
2.45 [0.21 ; 28.37 ] Pandit, 2021, Shashi Bhushan, 2021 2 0% 289 moderate not evaluable deathsdetailed results Li, 2021 1.04 [0.02; 53.73]
Pandit, 2021 0.95 [0.02; 50.33]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Synairgen SG016, 2020 0.16 [0.01; 3.31]
0.87 [0.16 ; 4.83 ] Li, 2021, Pandit, 2021, Shashi Bhushan, 2021, Synairgen SG016, 2020 4 0% 484 moderate not evaluable clinical deteriorationdetailed results Li, 2021 0.52 [0.02; 15.78]
Synairgen SG016, 2020 0.50 [0.18; 1.38]
0.50 [0.19 ; 1.33 ] Li, 2021, Synairgen SG016, 2020 2 0% 195 moderate not evaluable clinical improvementdetailed results Li, 2021 1.76 [1.10; 2.81]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Synairgen SG016, 2020 2.32 [1.07; 5.04]
1.64 [0.98 ; 2.76 ] Li, 2021, Shashi Bhushan, 2021, Synairgen SG016, 2020 3 33% 338 moderate not evaluable clinical improvement (14-day)detailed results Li, 2021 2.86 [1.24; 6.62]
Pandit, 2021 8.77 [0.94; 81.67]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
2.11 [0.60 ; 7.41 ] Li, 2021, Pandit, 2021, Shashi Bhushan, 2021 3 65% 375 moderate not evaluable clinical improvement (28-day)detailed results Li, 2021 4.26 [1.10; 16.44]
Synairgen SG016, 2020 3.15 [1.39; 7.14]
3.42 [1.70 ; 6.88 ] Li, 2021, Synairgen SG016, 2020 2 0% 195 moderate not evaluable clinical improvement (7-day)detailed results Li, 2021 1.83 [0.41; 8.14]
Shashi Bhushan, 2021 1.91 [1.03; 3.53]
1.90 [1.07 ; 3.35 ] Li, 2021, Shashi Bhushan, 2021 2 0% 316 moderate not evaluable clinical improvement (time to event analysis only)detailed results Li, 2021 1.76 [1.10; 2.81]
1.76 [1.10 ; 2.81 ] Li, 2021 1 0% 96 NA not evaluable death or ventilationdetailed results Synairgen SG016, 2020 0.38 [0.09; 1.63]
0.38 [0.09 ; 1.63 ] Synairgen SG016, 2020 1 0% NA not evaluable hospital dischargedetailed results Synairgen SG016, 2020 1.63 [0.61; 4.35]
1.63 [0.61 ; 4.35 ] Synairgen SG016, 2020 1 0% 101 NA not evaluable mechanical ventilationdetailed results Li, 2021 0.52 [0.02; 15.78]
0.52 [0.02 ; 15.78 ] Li, 2021 1 0% 94 NA not evaluable viral clearance detailed results Li, 2021 7.68 [0.91; 65.15]
Pandit, 2021 2.33 [0.55; 9.83]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
2.90 [1.64 ; 5.14 ] Li, 2021, Pandit, 2021, Shashi Bhushan, 2021 3 0% 375 moderate not evaluable viral clearance (time to event analysis only)detailed results Li, 2021 1.74 [1.10; 2.75]
1.74 [1.10 ; 2.75 ] Li, 2021 1 0% 96 NA not evaluable viral clearance by day 14detailed results Li, 2021 1.74 [0.71; 4.29]
Pandit, 2021 10.23 [1.12; 93.35]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
0.38 [0.00 ; 46.74 ] Li, 2021, Pandit, 2021, Shashi Bhushan, 2021 3 98% 1,453 moderate not evaluable viral clearance by day 7detailed results Li, 2021 2.20 [0.95; 5.10]
Pandit, 2021 2.33 [0.55; 9.83]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
2.52 [1.55 ; 4.09 ] Li, 2021, Pandit, 2021, Shashi Bhushan, 2021 3 0% 375 moderate not evaluable recoverydetailed results Synairgen SG016, 2020 2.19 [1.03; 4.67]
2.19 [1.03 ; 4.67 ] Synairgen SG016, 2020 1 0% 101 NA not evaluable serious adverse eventsdetailed results Pandit, 2021 0.95 [0.02; 50.33]
0.95 [0.02 ; 50.33 ] Pandit, 2021 1 0% 39 NA not evaluable adverse eventsdetailed results Pandit, 2021 1.68 [0.47; 5.97]
1.68 [0.47 ; 5.97 ] Pandit, 2021 1 0% 39 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-06 15:40 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290
